Tag: EFICAS

CARMAT Announces the First Implantation of Aeson® Within the Framework of The EFICAS Clinical Study in France

Coronary/Structural Heart by 0 comments

PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced the first implantation of its Aeson® […]

Continue Reading →

CARMAT is granted €13 million in national innovation funding to conduct the EFICAS study in France

Coronary/Structural Heart Financial by 0 comments

PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today […]

Continue Reading →